Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20126191 | 0.92 | RAB9A (0.43) | RAB9AHRH3CYP2C9CRBNNPC1 | |
| SCHEMBL20126311 | 0.85 | NPC1 (0.41) | RAB9AHRH3CYP2C9CRBNNPC1 | |
| SCHEMBL20126120 | 0.81 | RAB9A (0.37) | RAB9AHRH3CYP2C9CRBNNPC1 | |
| SCHEMBL20126144 | 0.81 | CRBN (0.34) | RAB9AHRH3CYP2C9CRBNNPC1 | |
| SCHEMBL12288978 | 0.74 | RAB9A (0.61) | RAB9AHRH3CYP2C9CRBNNPC1 | |
| SCHEMBL10766593 | 0.73 | RAB9A (0.51) | RAB9AHRH3CYP2C9CRBNNPC1 | |
| SCHEMBL10766598 | 0.73 | RAB9A (0.51) | RAB9AHRH3CYP2C9CRBNNPC1 | |
| SCHEMBL20126230 | 0.72 | CACNA2D1 (0.37) | HRH3CYP2C9KCNH2CYP3A4 | |
| SCHEMBL20126176 | 0.72 | CYP2C9 (0.32) | HRH3CYP2C9 | |
| SCHEMBL10764762 | 0.72 | CYP2C9 (0.50) | RAB9AHRH3CYP2C9CRBNNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127654-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-10 | — | — | US | disclosed |
| US-20180127654-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127654-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | DRD1, PLD1, DRD2 | RAB9A 2023/4885HRH3 85/4885CYP2C9 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.